{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:05:09Z","timestamp":1761901509279,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.msard.2020.102029","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T02:18:32Z","timestamp":1582683512000},"page":"102029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Localized sporotrichosis during natalizumab treatment in Multiple Sclerosis"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1303-9273","authenticated-orcid":false,"given":"Paula Teixeira","family":"Marques","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udia Suemi Kamoi","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia Machado Alves","family":"Bas\u00edlio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ros\u00e2ngela Lameira","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lineu Cesar","family":"Werneck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Jose","family":"Lorenzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosana Herminia","family":"Scola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102029_bib0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing Multiple Sclerosis","volume":"348","author":"Blumhardt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102029_bib0002","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for Multiple Sclerosis: updated","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.msard.2020.102029_bib0003","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1177\/1352458518770090","article-title":"New fungal infections associated with disease-modifying treatments in MS","volume":"24","author":"Correale","year":"2018","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2020.102029_bib0004","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1590\/abd1806-4841.2017279","article-title":"Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics","volume":"92","author":"Orofino-Costa","year":"2017","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.msard.2020.102029_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/mmy\/myu062","article-title":"Global epidemiology of sporotrichosis","volume":"53","author":"Chakrabarti","year":"2015","journal-title":"Med. Mycol."},{"issue":"3","key":"10.1016\/j.msard.2020.102029_bib0006","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1590\/S0004-282X2013000300002","article-title":"Natalizumab adverse events are rare in patients with Multiple Sclerosis","volume":"71","author":"Fragoso","year":"2013","journal-title":"Arq. Neuropsiquiatr."},{"issue":"11","key":"10.1016\/j.msard.2020.102029_bib0007","article-title":"Effect of natalizumab on circulating CD4+T-Cells in Multiple Sclerosis","volume":"7","author":"Christensen","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.msard.2020.102029_bib0011","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with Multiple Sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2020.102029_bib0008","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/ana.20859","article-title":"Natalizumab effects on immune cell responses in Multiple Sclerosis","volume":"59","author":"Niino","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.102029_bib0009","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jneuroim.2017.05.006","article-title":"CD4\/CD8 ratio during natalizumab treatment in Multiple Sclerosis patients","volume":"309","author":"Carotenuto","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2020.102029_bib0010","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing Multiple Sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"NEJM"},{"key":"10.1016\/j.msard.2020.102029_bib0012","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.imbio.2012.04.006","article-title":"Immunobiology Dendritic cell are able to differentially recognize Sporothrix schenckii antigens and promote Th1\/Th17 response in vitro","volume":"217","author":"Verdan","year":"2012","journal-title":"Immunobiology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482030105X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482030105X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:47:44Z","timestamp":1761900464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482030105X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":12,"alternative-id":["S221103482030105X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102029","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Localized sporotrichosis during natalizumab treatment in Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102029"}}